

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : A61K 39/395, 37/02	AI	(11) International Publication Number: WO 93/15764 (43) International Publication Date: 19 August 1993 (19.08.93)
(21) International Application Number: PCT/US93/00924 (22) International Filing Date: 2 February 1993 (02.02.93) (30) Priority data: 07/835,139 12 February 1992 (12.02.92) US (60) Parent Application or Grant (63) Related by Continuation US 07/835,139 (CIP) Filed on 12 February 1992 (12.02.92) (71) Applicant (for all designated States except US): BIOGEN, INC. [US/US]; 14 Cambridge Center, Cambridge, MA 02142 (US).		(72) Inventor; and (75) Inventor/Applicant (for US only): LOBB, Roy, R. [US/US]; 62 Loring Street, Westwood, MA 02090 (US). (74) Agents: McDONNELL, John, J. et al.; Allegretti & Witcoff, Ltd., 10 South Wacker Drive, Suite 3000, Chicago, IL 60606 (US). (81) Designated States: AU, CA, JP, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: TREATMENT FOR INFLAMMATORY BOWEL DISEASE (57) Abstract A method for the treatment of inflammatory bowel disease (IBD) is disclosed. The method comprises administration of an antibody, polypeptide or other molecule recognizing VLA-4, a surface molecule expressed on most types of white blood cells and involved in leukocyte adhesion to endothelium and other tissues in the gut. <div style="text-align: right; font-size: 2em; font-family: cursive;">AL</div>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NL	Netherlands
BE	Belgium	GN	Guinea	NO	Norway
BF	Burkina Faso	GR	Greece	NZ	New Zealand
BG	Bulgaria	HU	Hungary	PL	Poland
BJ	Benin	IE	Ireland	PT	Portugal
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SU	Sudan
CC	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SK	Slovak Republic
CI	Côte d'Ivoire	LI	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	MC	Monaco	TC	Togo
DE	Germany	MG	Madagascar	UA	Ukraine
DK	Denmark	ML	Mali	US	United States of America
ES	Spain	MN	Mongolia	VN	Viet Nam
FI	Finland				

-1-

TREATMENT FOR INFLAMMATORY BOWEL DISEASE

FIELD OF THE INVENTION

The present invention relates to a treatment for
5 inflammatory bowel disease (IBD). More particularly, this
invention relates to the use of antibodies recognizing the
integrin VLA-4 (very late antigen-4) in the treatment of
IBD.

BACKGROUND OF THE INVENTION

10 Inflammatory bowel disease, or IBD, is a
collective term encompassing ulcerative colitis and
Crohn's disease (ileitis), which are chronic inflammatory
disorders of the gastrointestinal tract. Ulcerative
colitis is confined to the large intestine (colon) and
15 rectum, and involves only the inner lining of the
intestinal wall. Crohn's disease may affect any section
of the gastrointestinal tract (i.e., mouth, esophagus,
stomach, small intestine, large intestine, rectum and
anus) and may involve all layers of the intestinal wall.
20 Both diseases are characterized by abdominal pain and
cramping, diarrhea, rectal bleeding and fever. The
symptoms of these diseases are usually progressive, and
sufferers typically experience periods of remission
followed by severe flareups.
25 IBD affects an estimated two million people in
the United States alone. Although IBD is not considered a
fatal illness, prolonged disease can lead to severe
malnutrition affecting growth or to the formation of
abscesses or intestinal scar tissue, leading in turn to
30 infection or bowel obstruction.

IBD has no cure, and the exact causes of IBD are
not yet understood. Conventional treatments for IBD have
involved anti-inflammatory drugs, immunosuppressive drugs

- 2 -

and surgery. Sulfasalazine and related drugs having the bioactive 5-amino-salicylic acid (5-ASA) moiety are widely used to control moderate IBD symptoms and to maintain remission. Severe inflammation is often treated with
5 powerful corticosteroids and sometimes ACTH or with immunosuppressants such as 6-mercaptopurine and azathioprine. The most common surgical treatments for severe chronic IBD are intestinal resections and, ultimately, colectomy, which is a complete cure only for
10 ulcerative colitis.

Severe side effects are associated with the drugs commonly prescribed for IBD, including nausea, dizziness, changes in blood chemistry (including anemia and leukopenia), skin rashes and drug dependence; and the
15 surgical treatments are radical procedures that often profoundly alter the everyday life of the patient. Accordingly, there is a great need for treatments for IBD that are effective yet less severe in their side effects and are less invasive of the IBD sufferer's body and
20 quality of life.

The search for the causes of IBD and more effective treatments has led several investigators to study diseased and normal tissue on a cellular level. This has led to observations of variations in the normal
25 content of intestinal mucin (Podolsky, 1988 [1]) and to the observation of colonic glycoproteins that emerge only in diseased tissue (Podolsky and Fournier, 1988a [2], 1988b [3]). Researchers have observed that the cell adhesion molecule ICAM-1 is expressed at elevated levels
30 in IBD tissue (Malizia et al., 1991 [4]). This molecule is thought to mediate leukocyte recruitment to sites of inflammation through adhesion to leukocyte surface ligands, i.e., LFA-1 (CD11a/CD18 complex) on all

- 3 -

leukocytes and Mac-1 (CD11b/CD18) on phagocytes. (See, e.g., Springer, 1990 [5].) Because flareups of IBD are often accompanied by increased concentrations of neutrophils and lymphocytes in the intestinal submucosa, blocking of interactions between endothelial cell receptors (such as ICAM-1) and their leukocyte ligands (such as LFA-1, Mac-1) has been proposed as a treatment for IBD.

Another cell adhesion molecule, VCAM-1 (vascular cell adhesion molecule-1) is expressed on inflamed endothelium and has been shown to recognize the $\alpha_4\beta_1$ integrin, VLA-4, expressed on the surface of all leukocytes except neutrophils (Springer, 1990 [5]). VCAM-1 also has been found to be expressed constitutively in noninflamed tissue, including Peyer's patch follicular dendritic cells (Freedman et al., 1990 [6]; Rice et al., 1991 [7]). Additionally, besides mediating cell adhesion events, VCAM-1 also has recently been determined to play a costimulatory role, through VLA-4, in T cell activation (Burkly et al., 1991 [8]; Damle and Arrufo, 1991 [9]; van Seventer et al., 1991 [10]). Accordingly, further study of VCAM-1 has been taken up to investigate whether it plays a role as a regulator of the immune response as well as a mediator of adhesion in vivo.

It has now been surprisingly discovered that administering anti-VLA-4 antibody significantly reduces acute inflammation in a primate model for IBD. Cotton top tamarins suffering from a spontaneous intestinal inflammation comparable to ulcerative colitis in humans that were treated with an anti-VLA-4 antibody (HP1/2) showed significant reduction in inflammation of biopsied intestinal tissue.

- 4 -

SUMMARY OF THE INVENTION

Accordingly, the present invention provides novel methods for the treatment of IBD and further provides new pharmaceutical compositions useful in the treatment of IBD. In particular, the present invention provides a method comprising the step of administering to an IBD sufferer an anti-VLA-4 antibody, such as antibody HP1/2. Also contemplated is the use of analogous antibodies, antibody fragments, soluble proteins and small molecules that mimic the action of anti-VLA-4 antibodies in the treatment of IBD.

DETAILED DESCRIPTION OF THE INVENTION

The technology for producing monoclonal antibodies is well known. Briefly, an immortal cell line (typically myeloma cells) is fused to lymphocytes (typically splenocytes) from a mammal immunized with whole cells expressing a given antigen, e.g., VLA-4, and the culture supernatants of the resulting hybridoma cells are screened for antibodies against the antigen. (See, generally, Kohler and Milstein, 1975 [11].)

Immunization may be accomplished using standard procedures. The unit dose and immunization regimen depend on the species of mammal immunized, its immune status, the body weight of the mammal, etc. Typically, the immunized mammals are bled and the serum from each blood sample is assayed for particular antibodies using appropriate screening assays. For example, anti-VLA-4 antibodies may be identified by immunoprecipitation of ¹²⁵I-labeled cell lysates from VLA-4-expressing cells. (See, Sanchez-Madrid et al., 1986 [13] and Hemler et al., 1987 [14].) Anti-VLA-4 antibodies may also be identified by flow cytometry, e.g., by measuring fluorescent staining of Ramos cells

- 5 -

incubated with an antibody believed to recognize VLA-4 (see, Elices et al., 1990 [15]). The lymphocytes used in the production of hybridoma cells typically are isolated from immunized mammals whose sera have already tested
5 positive for the presence of anti-VLA-4 antibodies using such screening assays.

Typically, the immortal cell line (e.g., a myeloma cell line) is derived from the same mammalian species as the lymphocytes. Preferred immortal cell lines
10 are mouse myeloma cell lines that are sensitive to culture medium containing hypoxanthine, aminopterin and thymidine ("HAT medium"). HAT-sensitive mouse myeloma cells may be fused to mouse splenocytes, e.g., using 1500 molecular weight polyethylene glycol ("PEG 1500"). Hybridoma cells
15 resulting from the fusion are then selected using HAT medium, which kills unfused and unproductively fused myeloma cells (unfused splenocytes die after several days because they are not transformed). Hybridomas producing a desired antibody are detected by screening the hybridoma
20 culture supernatants. For example, hybridomas prepared to produce anti-VLA-4 antibodies may be screened by testing the hybridoma culture supernatant for secreted antibodies having the ability to bind to a recombinant α -subunit-expressing cell line, such as transfected K-562 cells
25 (see, Elices et al., [15]).

To produce anti VLA-4-antibodies, hybridoma cells that test positive in such screening assays may be cultured in a nutrient medium under conditions and for a time sufficient to allow the hybridoma cells to secrete
30 the monoclonal antibodies into the culture medium. Tissue culture techniques and culture media suitable for hybridoma cells are well known. The conditioned hybridoma

- 6 -

culture supernatant may be collected and the anti-VLA-4 antibodies optionally further purified by well-known methods.

Alternatively, the desired antibody may be produced by injecting the hybridoma cells into the peritoneal cavity of a mouse primed with 2,6,10,14-tetramethylpentadecane (PRISTANE; Sigma Chemical Co., St. Louis MO). The hybridoma cells proliferate in the peritoneal cavity, secreting the antibody, which accumulates as ascites fluid. The antibody may be harvested by withdrawing the ascites fluid from the peritoneal cavity with a syringe.

Several anti-VLA-4 monoclonal antibodies have been previously described (see, e.g., Sanchez-Madrid et al., 1986 [12]; Hemler et al. (1987) [13]; Pulido et al. (1991) [14]). For the experiments herein, an anti-VLA-4 monoclonal antibody designated HP1/2 (obtained from Biogen, Inc., Cambridge, MA) was used. The variable regions of the heavy and light chains of the anti-VLA-4 antibody HP1/2 have been cloned, sequenced and expressed in combination with constant regions of human immunoglobulin heavy and light chains. Such a chimeric HP1/2 antibody is similar in specificity and potency to the murine HP1/2 antibody, and may be useful in methods of treatment according to the present invention. Similarly, humanized recombinant anti-VLA-4 antibodies may be useful in these methods. The HP1/2 V_H DNA sequence and its translated amino acid sequences are set forth in SEQ ID NO: 1 and SEQ ID NO: 2, respectively. The HP1/2 V_K DNA sequence and its translated amino acid sequence are set forth in SEQ ID NO: 3 and SEQ ID NO: 4, respectively.

- 7 -

Monoclonal antibodies such as HP1/2 and other anti-VLA-4 antibodies (e.g., Mab HP2/1, HP2/4, L25, P4C2) capable of recognizing the α chain of VLA-4 will be useful in the present invention. It is most preferred that the antibodies will recognize the B1 or B2 epitopes of the VLA- α chain (see, Pulido et al. (1991) [15]). While not wishing to be bound by one scientific theory, anti-VLA-4 antibodies used according to the method of the present invention may specifically inhibit, at least for an initial period, the migration of VLA-4-expressing leukocytes to inflamed sections of the gut. Or, the release of inflammatory mediators and cytokines by leukocytes already recruited to IBD tissue may be blocked by anti-VLA-4 antibodies that prevent some form of VCAM-1-mediated signal transduction, such as the T cell co-activation observed previously (e.g., Burkly et al. 1991 [8]). Monoclonal antibody HP1/2 has been shown to block leukocyte adhesion to VCAM-1-expressing cells but not to promote VLA-4-mediated T cell activation.

The method of the present invention comprises administering to a mammal suffering from inflammatory bowel disease a composition comprising an anti-VLA-4 antibody. The examples below set forth the results observed in cotton top tamarins. The physiological and histochemical similarities between a spontaneous chronic diffuse colitis observed in the cotton top tamarin (CTT) and IBD humans has been documented (see, e.g., Podolsky et al., 1985a [16], Podolsky et al., 1985b [17]). Prior studies have also demonstrated parallel responses in CTTs to therapeutic compounds used in the management of the human IBD (see, e.g., Madara et al., 1985 [18]). Accordingly, the results reported herein will be relevant

- 8 -

and applicable to, and the method claimed will be useful in any mammal, including humans, suffering from IBD.

The anti-VLA-4 antibody administered in accordance with the present invention may be administered prophylactically to a chronic IBD sufferer, to bring about or maintain remission of the disease; however, preferably the method of the present invention is used to treat acute flareups of the disease.

The anti-VLA-4 antibody can be administered in the form of a composition comprising an anti-VLA-4 antibody and a pharmaceutically acceptable carrier. Preferably, the composition will be in a form suitable for intravenous injection. For acute flareups of ulcerative colitis or Crohn's disease, dosages of from 0.05 mg/kg-patient/day to 5.0 mg/kg-patient/day (preferably from 0.5 mg/kg-patient/day to 2.0 mg/kg-patient/day) may be used, although higher or lower dosages may be indicated with consideration to the age, sensitivity, tolerance, and other characteristics of the patient; the acuteness of the flareup, the history and course of the disease, plasma level and half-life of the antibody employed and its affinity for its recognition site, and other similar factors routinely considered by an attending physician. For maintenance of remission from active disease, dosages from 0.05 mg/kg-patient/day to 5.0 mg/kg-patient/day (preferably from 0.5 mg/kg-patient/day to 2.0 mg/kg-patient/day) may be used, although higher or lower dosages may be indicated and employed with advantageous effects considering the age, sensitivity, tolerance, and other characteristics of the patient, the pattern of flareups, the history and course of the disease, the plasma level and half-life of the antibody employed and its affinity for its recognition site, and other similar factors

- 9 -

5 routinely considered by an attending physician. Dosages may be adjusted, for example, to provide a particular plasma level of antibody, e.g., in the range of 5-30 $\mu\text{g/ml}$, more preferably 10-15 $\mu\text{g/ml}$, for murine antibodies, and to maintain that level, e.g., for a period of time (e.g., 1 week) or until clinical results are achieved (e.g., flareup subsides). Chimeric and humanized antibodies, which would be expected to be cleared more slowly, will require lower dosages to maintain an effective plasma level. Also, antibodies or fragments having high affinity for VLA-4 will need to be administered less frequently or in lower doses than antibodies or antibody fragments of lesser affinity.

15 Suitable pharmaceutical carriers include, e.g., sterile saline, physiological buffer solutions and the like. The pharmaceutical compositions may additionally be formulated to control the release of the active ingredients or prolong their presence in the patient's system. Numerous suitable drug delivery systems are known for this purpose and include, e.g., hydrogels, hydroxymethylcellulose, microcapsules, liposomes, microemulsions, microspheres, and the like. Phosphate buffered saline (PBS) is a preferred carrier for injectible compositions.

25 It will also be recognized that for the purposes of the present invention, antibodies capable of binding to the α_4 subunit of VLA-4 must be employed. It is preferred that monoclonal antibodies be used.

30 In addition to naturally produced antibodies, suitable recombinant antibodies capable of binding to VLA-4 may alternatively be used. Such recombinant antibodies include antibodies produced via recombinant DNA

- 10 -

techniques, e.g., by transforming a host cell with a suitable expression vector containing DNA encoding the light and heavy immunoglobulin chains of the desired antibody, and recombinant chimeric antibodies, wherein

5 some or all of the hinge and constant regions of the heavy and/or the light chain of the anti-VLA-4 antibody have been substituted with corresponding regions of an immunoglobulin light or heavy chain of a different species (i.e., preferably the same species as the IBD sufferer

10 being treated, to minimize immune response to the administered antibody). (See, e.g., Jones et al., 1986 [19], Ward et al., 1989 [20], and U.S. Patent 4,816,397 (Boss et al.) [21], all incorporated herein by reference.) Recombinant antibodies specifically contemplated herein

15 include CDR-grafted antibodies or "humanized" antibodies, wherein the hypervariable regions of, e.g., murine antibodies are grafted onto framework regions of, e.g., a human antibody. (See, e.g., Riechmann et al., 1988 [22]; Man Sung Co et al., 1991 [23]; Brown, Jr., 1991 [24].)

20 Furthermore, VLA-4-binding fragments of anti-VLA-4 antibodies, such as Fab, Fab', F(ab')₂, and F(v) fragments; heavy chain monomers or dimers; light chain monomers or dimers; and dimers consisting of one heavy chain and one light chain are also contemplated herein.

25 Such antibody fragments may be produced by chemical methods, e.g., by cleaving an intact antibody with a protease, such as pepsin or papain, or via recombinant DNA techniques, e.g., by using host cells transformed with truncated heavy and/or light chain genes. Heavy and light

30 chain monomers may similarly be produced by treating an intact antibody with a reducing agent such as dithiothreitol or β -mercaptoethanol or by using host cells

- 11 -

transformed with DNA encoding either the desired heavy chain or light chain or both.

As an alternative to hybridoma technology, antibody fragments having the desired anti-VLA-4 specificities may be isolated by phage cloning methods. (See, e.g., Clackson et al., 1991 [25].)

Also, from the foregoing discussion it will be apparent that other polypeptides and molecules which bind to VLA-4 with sufficient specificity to inhibit VLA-4/VCAM-1 interactions or to inhibit transduction of VCAM-1-mediated signaling will be effective in the treatment of IBD in the same manner as anti-VLA-4 antibodies. For example, a soluble form of VCAM-1 (see, e.g., Osborn et al. 1989 [26]) or a fragment thereof may be administered to compete for the VLA-4 binding site, thereby leading to effects similar to the administration of anti-VLA-4 antibodies. Small molecules that mimic the binding domain of a VLA-4 ligand and fit the receptor domain of VLA-4 may also be employed. (See also, Devlin et al., 1990 [27], Scott and Smith, 1990 [28], and U.S. Patent 4,833,092 (Geysen) [29], all incorporated herein by reference.) The use of such VLA-4-binding polypeptides or molecules that effectively decrease inflammation in IBD tissue in treated subjects is contemplated herein as an alternative method for treatment of IBD.

It is also contemplated that anti-VLA-4 antibodies may be used in combination with other antibodies having a therapeutic effect on IBD. For instance, to the extent that the beneficial effects reported herein are due to the inhibition of leukocyte recruitment to endothelium, combinations of anti-VLA-4 antibodies with other antibodies that interfere with the adhesion between leukocyte antigens and endothelial cell

- 12 -

receptor molecules may be advantageous. For example, in addition to the use of anti-VLA-4 antibodies in accordance with this invention, the use of anti-ELAM-1 antibodies, anti-VCAM-1 antibodies, anti-ICAM-1 antibodies, anti-CDX
5 antibodies, anti-CD18 antibodies, and/or anti-LFA-1 antibodies may be advantageous.

When formulated in the appropriate vehicle, the pharmaceutical compositions contemplated herein may be administered by any suitable means such as orally,
10 intraesophageally or intranasally, as well as subcutaneously, intramuscularly, intravenously, intra-arterially, or parenterally. Ordinarily intravenous (i.v.) or parenteral administration will be preferred to treat flareup conditions; oral administration in a timed
15 release vehicle will be preferred to maintain remission.

Improvement for IBD patients as a result of the methods of this invention can be evaluated by any of a number of methods known to practitioners in this art. For example, improvement in observed symptomology such as the
20 Truelove-Witts criteria (see, e.g., Lichtiger, et al., 1990 [30]) may be used, or specimens of colon tissue may be biopsied and characterized histologically (see, e.g., Madara et al., 1985 [18]).

The methods and compositions of the present
25 invention will be further illuminated by reference to the following examples, which are presented by way of illustration and not of limitation.

EXAMPLE I

VCAM1 Expression in the Colon

30 Experiments were performed to determine whether active IBD involved the expression of endothelial cell surface proteins involved in leukocyte adhesion. Expression of VCAM-1 in colon tissue of IBD sufferers and

- 13 -

normal or uninvolved colon tissue controls was evaluated. Human colonoscopic biopsy tissue samples were obtained, with informed consent, and prepared as frozen sections by mounting in OCT compound (TissueTek) and quick freezing in isopentane/liquid nitrogen. The human colon samples were from normal colon, active ulcerative colitis colon (UC-active), inactive ulcerative colitis colon (UC-inactive), uninvolved ulcerative colitis colon (UC-uninvolved), active Crohn's Disease colon (CD-active), and uninvolved Crohn's Disease colon (CD-uninvolved).

Frozen sections (-4μ) were placed on gelatin-coated slides (1% gelatin, heated at 60°C for 1-2 min., air dried, 1% formaldehyde at room temp., air dried), air dried 30 minutes, fixed in acetone for ten minutes at 4°C , washed three times in PBS and treated with 0.3% H_2O_2 in methanol (30 min., room temp.). The slides were then washed with PBS for 30 minutes, incubated with dilute normal human serum (1:100), and incubated with anti-VCAM-1 antibody 4B9 (1:100; obtained as a gift from Dr. John Harlan) for 60 minutes at room temperature. Control slides were incubated with an anti-bovine serum albumin (anti-BSA) antibody (Sigma Chemical Co., St. Louis MO). The samples were then washed with PBS for 10 minutes and incubated with a secondary biotinylated rabbit anti-mouse immunoglobulin (Dako Corp., Santa Barbara, CA) for 60 minutes at room temperature, then visualized using avidin-linked peroxidase (VECTASTAIN, Vector Labs, Burlingame CA).

The results of these tests are set forth in the following TABLE I:

- 14 -

TABLE I
Endothelial Cell Staining In Human Tissue

	<u>Tissue (n)</u>	<u>VCAM-1 Expression</u>	
		<u>n</u>	<u>(%)</u>
5	Normal (11)	6	(54.4)
	UC active (23)	14	(60.9)
	UC inactive (8)	5	(62.5)
	UC uninvolved (10)	4	(40.0)
	CD active (9)	5	(55.5)
10	CD uninvolved (12)	7	(58.3)

These data confirm the observations such as those reported by Freedman et al. [6] and Rice et al. [7] that VCAM-1 is expressed in both IBD-involved colon tissue and in normal colon tissue. In both CD and UC tissues, VCAM-1 was observed by immunocytochemistry in about 60% of samples.

EXAMPLE II

Anti-VLA-4 Antibody Recognition of CTT White Blood Cells

An anti-VLA-4 monoclonal antibody (HP1/2, obtained from Biogen, Inc., Cambridge MA) was tested to confirm that it recognized an epitope on CTT leukocytes.

Blood samples (3 ml) from CTTs were heparinized and the CTT peripheral blood mononuclear leukocytes (PBLs) were isolated using a Ficoll-Hypaque gradient (Pharmacia) according to the manufacturer's instructions for isolation of human PBLs. CTT PBLs were examined for their ability to bind to the murine anti-human VLA-4 monoclonal antibodies HP1/2 and HP2/1 by FACS analysis using a Becton Dickinson FACStar and standard techniques (see, e.g., Lobb et al., 1991a [31]). Both monoclonal antibodies bound to

- 15 -

CTT PBLs, indicating that both human and CTT VLA4 have similar epitopes recognized by these two antibodies.

CTT PBLs were also observed to adhere to microtiter plates coated with immobilized recombinant soluble human VCAM-1 (Biogen, Inc.), which binding was blocked by HP1/2 and HP2/1. These results show that CTT PBLs bind to VCAM-1 in a VLA-4-dependent manner, and that HP1/2 and HP2/1 block the interaction of CTT VLA-4 with human VCAM-1. (Cf. Lobb et al., 1991b [32].)

EXAMPLE III

Cotton Top Tamarin Trials

A stock solution in sterile saline of the anti-VLA-4 antibody, HP1/2 (IgG1), and a placebo control (saline only), were prepared for administration to ten cotton top tamarins (CTTs) exhibiting symptoms of spontaneous colitis (i.e., diarrhea, etc.; see, Madara et al. [18]). Five CTTs received HP1/2 and five received placebo, by intravenous injection. The CTTs receiving HP1/2 were injected with 1 mg HP1/2 per day (i.e., about 2 mg/kg/day, based on approximate half-kilogram weight of a CTT) for eight days (on Days 0, 1, 2, 3, 4, 5, 6, and 7 of the trial). Colon tissue samples obtained from the animals were biopsied every other day (on Days 0, 2, 4, 6, 8, and 10 of the trial).

Data from the biopsies were used to determine an acute inflammation index for each animal, giving a semi-quantitative analysis of the course of the colitis. (See, Madara et al. [18].) The inflammation indices before the trial began (Day 0) and at the end of the trial at Day 10 are set forth in Table II, below: ("Treated CTTs" received antibody HP1/2; "Control CTTs" received placebo)

- 16 -

TABLE II

	<u>Treated CTTs</u>	<u>Day 0</u> <u>AII*</u>	<u>Day 10</u> <u>AII</u>
5	1	2	0
	2	1	0
	3	1	0
	4	2	0
	5	2	1
	MEAN	1.6	0.2
10	<u>Control CTTs</u>		
	C1	2	0
	C2	2	1
	C3	1	1
	C4	2	2
15	C5	2	2
	MEAN	1.8	1.2

* AII = acute inflammation index

These results show that treatment with anti-VLA-
 20 4 antibody resulted in a significant ($p < 0.01$) decrease
 in acute inflammation index.

EXAMPLE IV

The trial described in Example III was repeated
 using 14 CTTs, 7 receiving HP1/2 and 7 receiving placebo.
 25 The change in acute inflammation index from Day 0 to Day
 10 is set forth in Table III:

- 17 -

TABLE III

		<u>Day 0</u>	<u>Day 10</u>
	<u>Treated CTTs</u>	<u>AII</u>	<u>AII</u>
5	6	2	0
	7	2	0
	8	2	0
	9	2	0
	10	2	0
10	11	2	1
	12	2	2
	MEAN	2.0	0.43
	<u>Control CTTs</u>		
15	C6	2	2
	C7	2	2
	C8	1	1
	C9	2	1
	C10	2	1
	C11	2	0
20	C12	1	0
	MEAN	1.71	1.00

The foregoing results show a significant decrease in acute inflammation in the CTTs receiving HP1/2.

The foregoing examples are intended as an illustration of the method of the present invention and are not presented as a limitation of the invention as claimed hereinafter. From the foregoing disclosure, numerous modifications and additional embodiments of the invention will be apparent to those experienced in this art. For example, actual dosage used, the type of antibody, antibody fragment or analog used, mode of administration, exact composition, time and manner of

- 18 -

administration of the treatment, and many other features
all may be varied without departing from the above
description. All such modifications and additional
embodiments are within the contemplation of this
5 application and within the scope of the appended claims.

- 19 -

CITED PUBLICATIONS

- [1] D. Podolsky, "Colonic Glycoproteins in Ulcerative Colitis: Potential Meaning in Heterogeneity," Inflammatory Bowel Diseases: Basic Research and Clinical Implications, Falk Symposium, Titisee, Germany, June 7-9, 1987 (Kluwer Academic Publishers; Boston 1987) pp. 449-56.
- [2] D. Podolsky and D. Fournier, "Alterations in Mucosal Content of Colonic Glycoconjugates in Inflammatory Bowel Disease Defined by Monoclonal Antibodies," Gastroenterology, 95, pp. 379-87 (1988).
- [3] D. Podolsky and D. Fournier, "Emergence of Antigenic Glycoprotein Structures in Ulcerative Colitis Detected Through Monoclonal Antibodies," Gastroenterology, 95, pp. 371-8 (1988).
- [4] G. Malizia et al., "Expression of Leukocyte Adhesion Molecules by Mucosal Mononuclear Phagocytes in Inflammatory Bowel Disease," Gastroenterology, 100, pp. 150-9 (1991).
- [5] T. Springer, "Adhesion Receptors of the Immune System," Nature, 346, pp. 425-34 (August 1990).
- [6] A. Freedman et al., "Adhesion of Human B Cells to Germinal Centers in Vitro Involves VLA-4 and INCAM-110," Science, 249, pp. 1030-33 (1990).
- [7] G. E. Rice et al., "Vascular and Nonvascular Expression of INCAM-110," Amer. J. Pathology, 138(2), pp. 385-93 (1991).
- [8] L. Burkly, et al., "Signaling by Vascular Cell Adhesion Molecule-1 (VCAM-1) Through VLA-4 Promotes CD3-dependent T Cell Proliferation," Eur. J. Immunol., 21, pp. 2871-75 (1991).
- [9] N. Damle and A. Aruffo, "Vascular Cell Adhesion Molecule 1 Induces T-cell Antigen Receptor-dependent Activation of CD4⁺ T Lymphocytes," Proc. Natl. Acad. Sci. USA, 88, pp. 6403-7 (1991).

- 20 -

- [10] G. van Seventer et al., "Analysis of T Cell Stimulation by Superantigen Plus Major Histocompatibility Complex Class II Molecules or by CD3 Monoclonal Antibody: Costimulation by Purified Adhesion Ligands VCAM-1, ICAM-1, but Not ELAM-1," J. Exp. Medicine, 174, pp. 901-13 (1991).
- [11] Kohler and Milstein, "Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity," Nature, 256, pp. 495-7 (1975).
- [12] F. Sanchez-Madrid et al., "VLA-3: A novel polypeptide association within the VLA molecular complex: cell distribution and biochemical characterization," Eur. J. Immunol., 16, pp. 1343-9 (1986).
- [13] M. E. Hemler et al., "Characterization of the Cell Surface Heterodimer VLA-4 and Related Peptides," J. Biol. Chem., 262(24), pp. 11478-85 (1987).
- [14] M. Elices et al., "VCAM-1 on Activated Endothelium Interacts with the Leukocyte Integrin VLA-4 at a Site Distinct from the VLA-4/Fibronectin Binding Site," Cell, 60, pp. 577-84 (1990).
- [15] R. Pulido et al., "Functional Evidence for Three Distinct and Independently Inhibitable Adhesion Activities Mediated by the Human Integrin VLA-4," J. Biol. Chem., 266(16), pp. 10241-5 (1991).
- [16] D. Podolsky, et al., "Colonic Mucin Composition in Primates Selective Alterations Associated with Spontaneous Colitis in the Cotton-top Tamarin," Gastroenterology, 88, pp. 20-5 (1985).
- [17] D. Podolsky et al., "Spontaneous Colitis In Cotton-Top Tamarins: Histologic, Clinical and Biochemical Features of an Animal Model of Chronic Colitis," Digestive Diseases and Sciences, 30(4), Abstract, p. 396 (1985).
- [18] J. Madara et al., "Characterization of Spontaneous Colitis in Cotton-Top Tamarin (Saguinus oedipus) and Its Response to Sulfasalazine," Gastroenterology, 88, pp. 13-19 (1985).

- 21 -

- [19] P. Jones et al., "Replacing the Complementarity-Determining Regions in a Human Antibody with Those From a Mouse," Nature, 321, pp. 522-25 (1986).
- [20] E. Ward et al., "Binding Activities of a Repertoire of Single Immunoglobulin Variable Domains Secreted From Escherichia coli," Nature, 341, pp. 544-6 (1989).
- [21] U.S. Patent 4,816,397, Boss et al., "Multichain Polypeptides Or Proteins And Processes For Their Production", issued March 28, 1989.
- [22] L. Riechmann et al., "Reshaping Human Antibodies for Therapy," Nature, 332, pp. 323-7 (1988).
- [23] Man Sun Co et al., "Humanized Antibodies for Antiviral Therapy," Proc. Natl. Acad. Sci. USA, 88, pp. 2869-73 (1990).
- [24] P. Brown, Jr. et al., "Anti-Tac-H, a Humanized Antibody to the Interleukin 2 Receptor, Prolongs Primate Cardiac Allograft Survival," Proc. Natl. Acad. Sci. USA, 88, pp. 2663-7 (1990).
- [25] T. Clackson et al., "Making Antibody Fragments Using Phage Display Libraries," Nature, 352, pp. 624-28 (1991).
- [26] L. Osborn et al., "Direct Expression Cloning of Vascular Cell Adhesion Molecule 1, a Cytokine-induced Endothelial Protein That Binds to Lymphocytes," Cell, 59, pp. 1203-11 (1989).
- [27] J. Devlin et al., "Random Peptide Libraries: A Source of Specific Protein Binding Molecules," Science, 249, pp. 400-406 (1990).
- [28] J. Scott and G. Smith, "Searching for Peptide Ligands with an Epitope Library," Science, 249, pp. 386-90 (1990).
- [29] U.S. Patent 4,833,092, Geysen, "Method For Determining Mimotopes", issued May 23, 1989.
- [30] S. Lichtiger and D. Present, "Preliminary Report: Cyclosporin in Treatment of S vere Active Ulcerative Colitis," Lancet, 336, pp. 16-19 (1990).

- 22 -

- [31] R. Lobb et al., "Expression and Functional Characterization of a Soluble Form of Endothelial-Leukocyte Adhesion Molecule 1," J. Immunol., 147(1), pp. 124-29 (1991).
- [32] R. Lobb et al., "Expression and Functional Characterization of a Soluble Form of Vascular Cell Adhesion Molecule 1," Biochem. Biophys. Res. Commun., 178(3), pp. 1498-1504 (1991).

The foregoing documents are incorporated herein by reference.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

- (i) APPLICANT: Lobb, Roy R.
- (ii) TITLE OF INVENTION: Treatment for Inflammatory Bowel Disease
- (iii) NUMBER OF SEQUENCES: 4
- (iv) CORRESPONDENCE ADDRESS:
 - (A) ADDRESSEE: Allegretti & Witcoff, Ltd.
 - (B) STREET: 10 South Wacker Drive, Suite 3000
 - (C) CITY: Chicago
 - (D) STATE: IL
 - (E) COUNTRY: US
 - (F) ZIP: 60606
- (v) COMPUTER READABLE FORM:
 - (A) MEDIUM TYPE: Floppy disk
 - (B) COMPUTER: IBM PC compatible
 - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
 - (D) SOFTWARE: PatentIn Release #1.0, Version #1.25
- (vi) CURRENT APPLICATION DATA:
 - (A) APPLICATION NUMBER: PCT
 - (B) FILING DATE: 1 February 1993
 - (C) CLASSIFICATION:
- (viii) ATTORNEY/AGENT INFORMATION:
 - (A) NAME: McNicholas, Janet M.
 - (B) REGISTRATION NUMBER: 32,918
 - (C) REFERENCE/DOCKET NUMBER: 92,308-A; D003 CIP PCT
- (ix) TELECOMMUNICATION INFORMATION:
 - (A) TELEPHONE: 312-715-1000
 - (B) TELEFAX: 312-715-1234

(2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 360 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: cDNA

-24-

(ix) FEATURE:

(A) NAME/KEY: misc_feature

(B) LOCATION: 1

(D) OTHER INFORMATION: /note= "pBAG159 insert: HP1/2 heavy chain variable region; amino acid 1 is Glu (E) but Gln (Q) may be substituted"

(ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: 1..360

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

GTC AAA CTG CAG CAG TCT GGG GCA GAG CTT GTG AAG CCA GGG GCC TCA	48
Val Lys Leu Gln Gln Ser Gly Ala Glu Leu Val Lys Pro Gly Ala Ser	
2 6 11 16	
GTC AAG TTG TCC TGC ACA GCT TCT GGC TTC AAC ATT AAA GAC ACC TAT	96
Val Lys Leu Ser Cys Thr Ala Ser Gly Phe Asn Ile Lys Asp Thr Tyr	
21 26 31	
ATG CAC TGG GTG AAG CAG AGG CCT GAA CAG GGC CTG GAG TGG ATT GGA	144
Met His Trp Val Lys Gln Arg Pro Glu Gln Gly Leu Glu Trp Ile Gly	
36 41 46	
AGG ATT GAT CCT GCG AGT GGC GAT ACT AAA TAT GAC CCG AAG TTC CAG	192
Arg Ile Asp Pro Ala Ser Gly Asp Thr Lys Tyr Asp Pro Lys Phe Gln	
51 56 61	
GTC AAG GCC ACT ATT ACA GCG GAC ACG TCC TCC AAC ACA GCC TGG CTG	240
Val Lys Ala Thr Ile Thr Ala Asp Thr Ser Ser Asn Thr Ala Trp Leu	
66 71 76 81	
CAG CTC AGC AGC CTG ACA TCT GAG GAC ACT GCC GTC TAC TAC TGT GCA	288
Gln Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala	
86 91 96	
GAC GGA ATG TGG GTA TCA ACG GGA TAT GCT CTG GAC TTC TGG GGC CAA	336
Asp Gly Met Trp Val Ser Thr Gly Tyr Ala Leu Asp Phe Trp Gly Gln	
101 106 111	
GGG ACC ACG GTC ACC GTC TCC TCA	360
Gly Thr Thr Val Thr Val Ser Ser	
116 121	

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 120 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

-25-

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Val Lys Leu Gln Gln Ser Gly Ala Glu Leu Val Lys Pro Gly Ala Ser
2 6 11 16

Val Lys Leu Ser Cys Thr Ala Ser Gly Phe Asn Ile Lys Asp Thr Tyr
21 26 31

Met His Trp Val Lys Gln Arg Pro Glu Gln Gly Leu Glu Trp Ile Gly
36 41 46

Arg Ile Asp Pro Ala Ser Gly Asp Thr Lys Tyr Asp Pro Lys Phe Gln
51 56 61

Val Lys Ala Thr Ile Thr Ala Asp Thr Ser Ser Asn Thr Ala Trp Leu
66 71 76 81

Gln Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala
86 91 96

Asp Gly Met Trp Val Ser Thr Gly Tyr Ala Leu Asp Phe Trp Gly Gln
101 106 111

Gly Thr Thr Val Thr Val Ser Ser
116 121

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 318 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 1..318
- (D) OTHER INFORMATION: /product= "HP1/2 light chain variable region"

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (B) LOCATION: 1
- (D) OTHER INFORMATION: /note= "pBAG172 insert: HP1/2 light chain variable region"

-26-

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

AGT ATT GTG ATG ACC CAG ACT CCC AAA TTC CTG CTT GTT TCA GCA GGA	48
Ser Ile Val Met Thr Gln Thr Pro Lys Phe Leu Leu Val Ser Ala Gly	
1 5 10 15	
GAC AGG GTT ACC ATA ACC TGC AAG GCC AGT CAG ACT GTG ACT AAT GAT	96
Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Ser Val Thr Asn Asp	
20 25 30	
GTA GCT TGG TAC CAA CAG AAG CCA GGG CAG TCT CCT AAA CTG CTG ATA	144
Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile	
35 40 45	
TAT TAT GCA TCC AAT CGC TAC ACT GGA GTC CCT GAT CGC TTC ACT GGC	192
Tyr Tyr Ala Ser Asn Arg Tyr Thr Gly Val Pro Asp Arg Phe Thr Gly	
50 55 60	
AGT GGA TAT GGG ACG GAT TTC ACT TTC ACC ATC AGC ACT GTG CAG GCT	240
Ser Gly Tyr Gly Thr Asp Phe Thr Phe Thr Ile Ser Thr Val Gln Ala	
65 70 75 80	
GAA GAC CTG GCA GTT TAT TTC TGT CAG CAG GAT TAT AGC TCT CCG TAC	288
Glu Asp Leu Ala Val Tyr Phe Cys Gln Gln Asp Tyr Ser Ser Pro Tyr	
85 90 95	
ACG TTC GGA GGG GGG ACC AAG CTG GAG ATC	318
Thr Phe Gly Gly Thr Lys Leu Glu Ile	
100 105	

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 106 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

Ser Ile Val Met Thr Gln Thr Pro Lys Phe Leu Leu Val Ser Ala Gly	
1 5 10 15	
Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Ser Val Thr Asn Asp	
20 25 30	
Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile	
35 40 45	

-27-

Tyr Tyr Ala Ser Asn Arg Tyr Thr Gly Val Pro Asp Arg Phe Thr Gly
50 55 60

Ser Gly Tyr Gly Thr Asp Phe Thr Phe Thr Ile Ser Thr Val Gln Ala
65 70 75 80

Glu Asp Leu Ala Val Tyr Phe Cys Gln Gln Asp Tyr Ser Ser Pro Tyr
85 90 95

Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile
100 105

- 28 -

CLAIMS:

1. A method for the treatment of inflammatory bowel disease comprising administering to a mammal suffering from inflammatory bowel disease a composition
5 comprising an anti-VLA-4 antibody.
2. The method of Claim 1, wherein the anti-VLA-4 antibody composition is administered intravenously.
3. The method of Claim 1, wherein the anti-VLA-4 antibody is selected from the group consisting of
10 HP1/2, HP2/1, HP2/4, L25, and P4C2.
4. The method of Claim 1, wherein the anti-VLA-4 antibody is HP1/2, or a fragment thereof capable of binding to VLA-4.
5. The method of Claim 1, wherein the
15 composition is administered at a dosage so as to provide from 0.05 to 5.0 mg/kg of antibody, based on the weight of the inflammatory bowel disease sufferer.
6. The method of Claim 5, wherein the
20 composition is administered at a dosage so as to provide 0.5 to 2.0 mg/kg of antibody, based on the weight of the inflammatory bowel disease sufferer.
7. The method according to Claim 1, wherein the composition is administered in an amount effective to provide a plasma level of antibody in the mammal of 10-15
25 µg/ml.
8. The method according to Claim 1, wherein the mammal is a human.
9. The method of Claim 8, wherein the mammal suffers from ulcerative colitis.
- 30 10. The method of Claim 8, wherein the mammal suffers from Crohn's Disease.

- 29 -

11. The method of Claim 1, wherein the composition is administered during an acute flareup of the inflammatory bowel disease.

12. A method for the treatment of inflammatory
5 bowel disease comprising administering to a mammal suffering from inflammatory bowel disease an antibody, a recombinant antibody, a chimeric antibody, fragments of such antibodies, a polypeptide or a small molecule capable of binding to the α subunit of VLA-4, or combinations of
10 any of the foregoing, in an amount effective to provide relief to said mammal.

13. The method of Claim 12, wherein the antibody, polypeptide or molecule is selected from monoclonal antibody HP1/2; Fab, Fab', F(ab'), or F(v)
15 fragments of such antibody; soluble VCAM-1 polypeptides; or small molecules that bind to the VCAM-1-binding domain of VLA-4.

14. The method of Claim 12, wherein the composition comprises a plurality of anti-VLA-4 monoclonal
20 antibodies or VLA-4-binding fragments thereof.

15. The method of Claim 12, wherein the composition includes, in addition to anti-VLA-4, an anti-ELAM-1 antibody, an anti-ICAM-1 antibody, an anti-VCAM-1 antibody, an anti-CDX antibody, an anti-LFA-1 antibody, an
25 anti-CD18 antibody or combinations of any such antibodies.

16. The method of Claim 12, wherein the anti-VLA-4 antibody is HP1/2, or a fragment thereof capable of binding to VLA-4.

- 30 -

17. The method of Claim 12, wherein the composition is administered at a dosage so as to provide from 0.05 to 5.0 mg/kg of antibody, antibody fragment, polypeptide or small molecule, based on the weight of the
5 inflammatory bowel disease sufferer.

18. The method of Claim 17, wherein the composition is administered at a dosage so as to provide 0.5 to 2.0 mg/kg of antibody, antibody fragment, polypeptide or small molecule, based on the weight of the
10 inflammatory bowel disease sufferer.

19. The method according to Claim 12, wherein the composition is administered in an amount effective to provide a plasma level of antibody in the mammal of 10-15 μ g/ml.

15 20. A pharmaceutical composition effective to significantly reduce acute inflammation in IBD tissues in an IBD sufferer, consisting essentially of a monoclonal antibody recognizing VLA-4 in a pharmaceutically acceptable carrier.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 93/00924

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) ⁶ According to International Patent Classification (IPC) or to both National Classification and IPC Int.Cl. 5 A61K39/395; A61K37/02		
II. FIELDS SEARCHED		
Minimum Documentation Searched ⁷		
Classification System	Classification Symbols	
Int.Cl. 5	A61K	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁸		
III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹		
Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
X	WO,A,9 200 751 (NOVO NORDISK A/S)	12, 13,
Y	23 January 1992 see claims 1,2,7,9-15,18-28	17, 18 1-11, 14-16, 19, 20
	---	-/--
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>¹⁰ Special categories of cited documents: ¹⁰</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"A" document member of the same patent family</p> </div> </div>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search		Date of Mailing of this International Search Report
21 JUNE 1993		08 -07- 1993
International Searching Authority		Signature of Authorized Officer
EUR PEAN PATENT OFFICE		RYCKEBOSCH A.O.

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No.
Y	<p>PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA. vol. 88, no. 16, 15 August 1991, WASHINGTON US pages 7430 - 7433 P.F. WELLER ET AL. 'HUMAN EOSINOPHIL ADHERENCE TO VASCULAR ENDOTHELIUM MEDIATED BY BINDING TO VASCULAR CELL ADHESION MOLECULE 1 AND ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1.' see page 7431, right column, line 1 - page 7432, right column, line 28 see page 7433, left column, line 15 - line 25</p> <p>---</p>	1-11, 14-16, 19,20
A	<p>EP,A,0 346 078 (THE ROCKEFELLER UNIVERSITY) 13 December 1989 see claims 1-5,9,13-16,18</p> <p>---</p>	12,15
A	<p>EP,A,0 314 863 (BAYLOR COLLEGE OF MEDICINE) 10 May 1989 see claims</p> <p>---</p>	12,15
P,Y	<p>GASTROENTEROLOGY vol. 103, no. 3, September 1992, NEW YORK, N.Y., US pages 840 - 847 M. KOIZUMI ET AL. 'EXPRESSION OF VASCULAR ADHESION MOLECULES IN INFLAMMATORY BOWEL DISEASE.' see the whole document</p> <p>-----</p>	1-11, 14-16, 19,20

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 93/00924

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Remark : Although claims 1-19 are directed to a method of treatment of the human/animal body the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

**ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO.**

US 9300924
SA 70082

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

21/06/93

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9200751	23-01-92	AU-A- 8205591	04-02-92
EP-A-0346078	13-12-89	US-A- 5147637	15-09-92
		AU-B- 620100	13-02-92
		AU-A- 3608489	14-12-89
		JP-A- 2104534	17-04-90
EP-A-0314863	10-05-89	AU-A- 1550988	27-07-89
		AU-A- 2633388	27-07-89
		JP-A- 1135724	29-05-89